Novartis Signs an Agreement with NHS to Commercialize Leqvio (inclisiran) for the Treatment of Cardiovascular Disease
Shots:
- The agreement follows the NICE recommendation to deliver Leqvio via a population health management approach for high-risk cardiovascular patients across England
- The NICE recommendation was based on Novartis’s ORION clinical research program including P- III trials ORION-9/10/11 evaluating the safety- efficacy- and tolerability of inclisiran in 3-600 patients with CVD which showed that the therapy-maintained LDL-C reduction through 6mos. dosing interval
- Inclisiran is the 1st siRNA therapy for the reduction of LDL-C levels via RNAi & is licensed in the EU for the treatment of adults with primary hypercholesterolaemia or mixed dyslipidaemia as an adjunct to diet
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com